Primary pulmonary artery sarcoma masquerading as pulmonary thromboembolism: a rare diagnosis unveiled [0.03%]
误诊为肺栓塞的原发性肺动脉肉瘤：一种罕见的诊断
Abhishek Mahajan,Bharat Rekhi,Siddhartha Laskar et al.
Abhishek Mahajan et al.
Background: Primary pulmonary artery sarcomas are rare malignant vascular tumors and carry a very poor prognosis. Due to overlapping clinical and radiological features, the differentiation between pulmonary artery thrombo...
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes [0.03%]
过表达的PRAME在某些肉瘤亚型中是一种潜在的免疫治疗靶点
Jason Roszik,Wei-Lien Wang,John A Livingston et al.
Jason Roszik et al.
Background: PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors, including sarcoma, and PRAME-specific therapies ...
Disseminated and late metastatic disease from nasal pit leiomyosarcoma after radical surgical resection. Case report of a singular presentation of a rare disease [0.03%]
鼻平滑肌肉瘤术后继发弥散性和晚期转移性疾病。罕见疾病特殊表现的病例报告
Enrico Pinotti,Marta Sandini,Simone Famularo et al.
Enrico Pinotti et al.
Background: Leiomyosarcoma of the head and neck is a rare cancer with high local aggressiveness. Radical surgery and adjuvant treatment offer the best chance for cure, nonetheless 5-years recurrence rate remains high. Des...
Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's) [0.03%]
抗血管生成作用于进行性实体瘤型小圆细胞肿瘤患者：来自法国全国登记处的关于肉瘤外标签靶向治疗（OUTC）的数据
Sarah Bétrian,Christophe Bergeron,Jean-Yves Blay et al.
Sarah Bétrian et al.
Background: Desmoplastic small round cell tumor (DSRCT) is a very rare mesenchymal tumor that mainly affects teenagers and young adults with a mean age at diagnosis around 20-25 years. Although initial management still ne...
Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases [0.03%]
组蛋白H3.3热点突变型骨肉瘤的临床和分子特征分析
Christian Koelsche,Daniel Schrimpf,Lars Tharun et al.
Christian Koelsche et al.
Background: Histone 3.3 (H3.3) hotspot mutations in bone tumors occur in the vast majority of giant cell tumors of bone (GCTBs; 96%), chondroblastomas (95%) and in a few cases of osteosarcomas. However, clinical presentat...
IDH1 or - 2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas [0.03%]
IDH1或IDH2基因突变不能预测软骨肉瘤的预后且不会造成5-羟甲基胞嘧啶丢失或组蛋白修饰改变
Arjen H G Cleven,Johnny Suijker,Georgios Agrogiannis et al.
Arjen H G Cleven et al.
Background: Mutations in isocitrate dehydrogenase (IDH)1 or -2 are found in ~50% of conventional central chondrosarcomas and in up to 87% of their assumed benign precursors enchondromas. The mutant enzyme acquires the act...
Erratum to: Osteosarcoma follow-up: chest X-ray or computed tomography? [0.03%]
骨肉瘤术后随访：胸部X线片还是CT？-附一条书眉注记
Anna Paioli,Michele Rocca,Luca Cevolani et al.
Anna Paioli et al.
[This corrects the article DOI: 10.1186/s13569-017-0067-5.].
Published Erratum
Clinical sarcoma research. 2017 May 3:7:7. DOI:10.1186/s13569-017-0073-7 2017
UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST) [0.03%]
英国胃肠道间质瘤(GIST)治疗临床实践指南
Ian Judson,Ramesh Bulusu,Beatrice Seddon et al.
Ian Judson et al.
Background: Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues. Gastrointestinal stromal tumour (GIST) is the commonest STS and arises within the wall of the gastrointestinal (GI) tract. While most...
Two years survival of primary cardiac leiomyosarcoma managed by surgical and adjuvant therapy [0.03%]
手术和综合治疗原发心脏平滑肌肉瘤的二年生存率分析
K Behi,M Ayadi,E Mezni et al.
K Behi et al.
Background: Cardiac tumors are a very rare entity. Leiomyosarcoma represents less than 1% of cases. Case presentation: a 51-year-old wo...
Case Reports
Clinical sarcoma research. 2017 Mar 9:7:5. DOI:10.1186/s13569-017-0069-3 2017
How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience [0.03%]
临床试验中心如何能改善罕见肿瘤的独立临床研究：意大利肉瘤集团的经验
Emanuela Marchesi,Celeste Cagnazzo,Irene Quattrini et al.
Emanuela Marchesi et al.
Background: The Italian Sarcoma Group (ISG) is a nonprofit group of professionals established in 1997 aimed to improve the quality of care and promote the independent research in sarcomas. The increased regulatory require...